Filing Flows › Comparisons › DNA vs MAZE
Ginkgo Bioworks Holdings vs Maze Therapeutics: DNA and MAZE compared
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $20.0M for Maze Therapeutics (Q1 2026). Maze Therapeutics is more profitable, with an operating margin of -132.8% against -290.5%.
Where the money goes: DNA and MAZE
Ginkgo Bioworks Holdings (DNA) · Q2 2026
Ginkgo Bioworks Holdings, Q2 2026: revenue $20.2M (-48% year over year), operating margin -290.5%, net loss $46.7M, operating cash flow −$44.3M. The chart follows the revenue to costs, profit and cash.
Maze Therapeutics (MAZE) · Q1 2026
Maze Therapeutics, Q1 2026: revenue $20.0M, operating margin -132.8%, net loss $24.2M, operating cash flow −$39.1M. The chart follows the revenue to costs, profit and cash.
| Ginkgo Bioworks Holdings (DNA) | Maze Therapeutics (MAZE) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $20.2M | $20.0M |
| Revenue growth, Y/Y | -48% | — |
| Operating margin | -290.5% | -132.8% |
| Net earnings | −$46.7M | −$24.2M |
| Net margin | -231.7% | -121.0% |
| Operating cash flow | −$44.3M | −$39.1M |
Questions
Which is bigger, Ginkgo Bioworks Holdings or Maze Therapeutics?
Ginkgo Bioworks Holdings is the larger company: $20.2M of revenue in its latest quarter (Q2 2026) against $20.0M for Maze Therapeutics (Q1 2026).
Is Ginkgo Bioworks Holdings or Maze Therapeutics growing faster?
Maze Therapeutics is more profitable, with an operating margin of -132.8% against -290.5%.
More: Ginkgo Bioworks Holdings earnings · how Ginkgo Bioworks Holdings makes money · Maze Therapeutics earnings · how Maze Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 6, 2026; 10-Q filed May 12, 2026). Fiscal quarters can end on different dates. Not investment advice.